[go: up one dir, main page]

SG11201501877WA - Combined treatment with netrin-1 interfering drug and chemotherapeutic drug - Google Patents

Combined treatment with netrin-1 interfering drug and chemotherapeutic drug

Info

Publication number
SG11201501877WA
SG11201501877WA SG11201501877WA SG11201501877WA SG11201501877WA SG 11201501877W A SG11201501877W A SG 11201501877WA SG 11201501877W A SG11201501877W A SG 11201501877WA SG 11201501877W A SG11201501877W A SG 11201501877WA SG 11201501877W A SG11201501877W A SG 11201501877WA
Authority
SG
Singapore
Prior art keywords
drug
netrin
combined treatment
interfering
chemotherapeutic
Prior art date
Application number
SG11201501877WA
Inventor
Patrick Mehlen
Andréa Paradisi
Pascale Nony
Original Assignee
Netris Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Netris Pharma filed Critical Netris Pharma
Publication of SG11201501877WA publication Critical patent/SG11201501877WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/282Platinum compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201501877WA 2012-09-12 2013-09-12 Combined treatment with netrin-1 interfering drug and chemotherapeutic drug SG11201501877WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261700158P 2012-09-12 2012-09-12
EP12306100.4A EP2708231A1 (en) 2012-09-12 2012-09-12 Combined treatment with netrin-1 interfering drug and chemotherapeutic drug
PCT/EP2013/068937 WO2014041088A2 (en) 2012-09-12 2013-09-12 Combined treatment with netrin-1 interfering drug and chemotherapeutic drug

Publications (1)

Publication Number Publication Date
SG11201501877WA true SG11201501877WA (en) 2015-04-29

Family

ID=46924380

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201501877WA SG11201501877WA (en) 2012-09-12 2013-09-12 Combined treatment with netrin-1 interfering drug and chemotherapeutic drug

Country Status (15)

Country Link
US (1) US9895439B2 (en)
EP (2) EP2708231A1 (en)
JP (1) JP6467604B2 (en)
KR (1) KR102424439B1 (en)
CN (2) CN110522913A (en)
AU (1) AU2013314320B2 (en)
BR (1) BR112015005443A2 (en)
CA (1) CA2884834C (en)
ES (1) ES2702733T3 (en)
HK (1) HK1208379A1 (en)
IL (1) IL237702B (en)
MX (1) MX375941B (en)
SG (1) SG11201501877WA (en)
WO (1) WO2014041088A2 (en)
ZA (1) ZA201502269B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2893939A1 (en) * 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody
CN105031611B (en) * 2015-06-18 2018-02-09 中国医学科学院基础医学研究所 Purposes of the albumen of netrin 1 in the medicine for oncotherapy is prepared
AR106543A1 (en) 2015-11-02 2018-01-24 Netris Pharma NTN1 NEUTRALIZING AGENT COMBINATION THERAPY WITH DRUGS THAT INHIBIT EPIGENTICAL CONTROL
CN105861505A (en) * 2016-05-31 2016-08-17 东北师范大学 UNC5A-targeted-silenced shRNA (short hairpin ribonucleic acid)
CA3045302A1 (en) * 2016-11-29 2018-06-07 Health Research, Inc. Methods and compositions for cancer therapy
WO2018127570A1 (en) 2017-01-05 2018-07-12 Netris Pharma Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs
CN112812167B (en) * 2021-01-06 2023-04-11 东北师范大学 Nerin-1 mimic peptide for promoting cell survival, netrin-1 truncated polypeptide and application thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
AU2001293870A1 (en) 2000-10-16 2002-04-29 Bayer Aktiengesellschaft Regulation of human netrin binding membrane receptor unc5h-1
US7312243B1 (en) * 2003-08-29 2007-12-25 Jay Pravda Materials and methods for treatment of gastrointestinal disorders
WO2005074556A2 (en) 2004-01-30 2005-08-18 The General Hospital Corporation Netrin compositions and methods of use thereof
US20080038255A1 (en) 2004-06-04 2008-02-14 Aplied Research Systems Ars Holding N.V. Splice Variant of Unc5h2
CA2573720A1 (en) 2004-07-14 2006-02-23 University Of Utah Research Foundation Netrin-related compositions and uses
JP5089397B2 (en) 2004-11-22 2012-12-05 サントル ナシオナル ドゥ ラ ルシェルシェ シアンティフィク Mutant netrin 4, fragments thereof and their use as drugs
US20060153840A1 (en) 2005-01-12 2006-07-13 Anne Eichmann Methods for preventing or treating a condition or a disease associated with angiogenesis
KR101587932B1 (en) 2006-02-28 2016-01-22 상뜨로 나쇼날 드 라 러쉐르쉐 샹띠피크 Screening for anti-cancer compounds using netrin-1 activity
WO2009141440A1 (en) 2008-05-21 2009-11-26 Centre National De La Recherche Scientifique (Cnrs) Netrin-1 overexpression as a biological marker and a survival factor for aggressive neuroblastoma
AR074369A1 (en) 2008-11-20 2011-01-12 Genentech Inc ANTI-UNC 5B ANTIBODIES (NETRINE RECEIVER) AND METHODS OF USE
EP2208738A1 (en) * 2009-01-09 2010-07-21 Centre National pour la Recherche Scientifique (CNRS) Method for the selection of endothelial cells death inducers via netrin-1 and its applications
MX2013001836A (en) 2010-08-26 2013-07-29 Hoffmann La Roche Recombinant fc-fusion protein of the fifth fibronectin type iii domain of dcc.

Also Published As

Publication number Publication date
WO2014041088A3 (en) 2014-07-03
EP2895173B1 (en) 2018-11-14
HK1208379A1 (en) 2016-03-04
EP2708231A1 (en) 2014-03-19
IL237702B (en) 2018-11-29
BR112015005443A2 (en) 2017-12-05
JP6467604B2 (en) 2019-02-13
KR20150079599A (en) 2015-07-08
MX375941B (en) 2025-03-07
ZA201502269B (en) 2019-05-29
US20150246116A1 (en) 2015-09-03
KR102424439B1 (en) 2022-07-21
AU2013314320B2 (en) 2017-04-06
CN104853756A (en) 2015-08-19
US9895439B2 (en) 2018-02-20
JP2015529675A (en) 2015-10-08
ES2702733T3 (en) 2019-03-05
CN110522913A (en) 2019-12-03
CA2884834A1 (en) 2014-03-20
AU2013314320A1 (en) 2015-04-02
CA2884834C (en) 2020-11-17
EP2895173A2 (en) 2015-07-22
WO2014041088A2 (en) 2014-03-20
AU2013314320A2 (en) 2015-04-09
MX2015003343A (en) 2015-10-22

Similar Documents

Publication Publication Date Title
IL274988A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
IL234628A0 (en) Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
SG11201501790VA (en) Multi-organ-chip with improved life time and homoeostasis
EP2828258A4 (en) Novelpyridopyrimidine derivatives and use thereof
EP2939702A4 (en) Catheter balloon and catheter
GB2500628B (en) Medical balloon with particles therein
IL239369A0 (en) Pirocyclic morphinans and their use
EP2867209A4 (en) Compounds and therapeutic uses thereof
EP2867239A4 (en) Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
SG10201701828WA (en) Peptides and their uses
ZA201502269B (en) Combined treatment with netrin-1 interfering drug and chemotherapeutic drug
PL2852537T3 (en) Infusion packet and its manufacture
GB201211775D0 (en) An electrode and use thereof
ZA201407276B (en) Polypeptides and their use
SG11201504482VA (en) Beta-hexosyl-transferases and uses thereof
EP2940008A4 (en) Novel benzazepine derivative and pharmaceutical use thereof
PL2852423T3 (en) Inhaler and capsule for an inhaler
GB201208199D0 (en) Inhaler and associated capsule chamber
GB201222541D0 (en) Kiddibidet and pottibidet
IL218974A0 (en) Conaction bitwen coutch and playels
GB201202021D0 (en) Co-sleeper and breastfeeder
GB201216381D0 (en) New compounds and medical uses
GB201208970D0 (en) New compounds and medical uses
GB201214769D0 (en) Methodsa and peptides